To determine the extent of serglycin expression in myeloma patients, we analyzed the GEP data bases from the CoMMpass (Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile) database interim analysis IA9 (http://research.themmrf.org), with the objective of assessing the effects of serglycin gene expression in 664 myeloma patients who have data available [29]. The gene discussed is SRGN; the disease is AL amyloidosis.